RESEARCHER PROFILE
David L. Rimm
D
Yale University
David L. Rimm works in Cancer Immunotherapy and Biomarkers, Breast Cancer Treatment Studies, Cutaneous Melanoma Detection and Management, AI in cancer detection, Head and Neck Cancer Studies. Recorded institutional associations include Yale University.
1,486Publications
70,716Citations
134H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
X-Tile
2004 · 3,744 citationsThe evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
2014 · 3,113 citationsArtificial intelligence in digital pathology — new tools for diagnosis and precision oncology
2019 · 1,685 citationsPD-L1 as a biomarker of response to immune-checkpoint inhibitors
2021 · 1,558 citationsEstrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
2020 · 1,553 citationsIntegrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
2005 · 1,549 citationsResidual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
2009 · 1,412 citationsAdhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the αEβ7 integrin
1994 · 1,177 citationsQuantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
2015 · 837 citationsValidation of Tissue Microarray Technology in Breast Carcinoma
2000 · 799 citationsAssessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
2017 · 799 citationsMolecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable Prognosis
2006 · 796 citationsImpaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2017 · 782 citationsAutomated subcellular localization and quantification of protein expression in tissue microarrays
2002 · 764 citationsA Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
2017 · 763 citationsProgrammed death ligand-1 expression in non-small cell lung cancer
2013 · 755 citationsAssessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
2020 · 753 citationsAlpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex.
1995 · 735 citationsAssessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
2017 · 709 citationsSiglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
2019 · 679 citationsImmunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
2019 · 667 citationsA proposal for validation of antibodies
2016 · 621 citationsComparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
2019 · 607 citationsAntibody validation
2010 · 589 citationsRAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
2015 · 534 citations
